fashion -WSS

fashion

author：focus 2025-09-28 00:53:53 - browse：138

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Physician subsidies by hospitals soar in wake of No Surprises Act

knowledge

WSS

Paying for Covid pills will soon shift to insurers

Senate panel to vote on hospitals, PBMs, prisoner care

FDA has safety concerns on CRISPR

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Physician subsidies by hospitals soar in wake of No Surprises Act

Public health communication lessons from Covid

entertainment

fashion

focus

Affirmative action in medical school literally saved lives

Hospitals, health systems can help patients avoid medical debt

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CDC recommends rationing of RSV shot due to shortages

Peter Hotez and the public health issue of online harassment

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Walensky prepares to leave CDC — and Congress — behind

Diversifying clinical trials isn't enough to close racial gaps: study

At least 13 dead in Texas as scorching temps continue

Alexander Hamilton and the argument for universal insurance

leisure time

First Opinion Podcast: How to protect health care in times of war

First Opinion Podcast: How to protect health care in times of war

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Interest rates are at a 22

The pink breast cancer awareness ribbon needs a redesign

hotspot

hotspot

knowledge

knowledge